Cantargia signs agreement with Patheon Biologics B.V. for production of antibody CAN04

Booking.com

Cantargia AB (publ) and Patheon Biologics B.V. (part of ThermoFischer Scientific) have signed an agreement regarding future production of the antibody CAN04 (nidanilimab). CAN04 is currently in phase IIa clinical development for non-small cell lung cancer and pancreatic cancer. Hereby, Cantargia secures additional production capacity for future clinical trials.
The antibody CAN04 is currently investigated in a European phase IIa clinical trial for treatment of patients with non-small cell lung cancer or pancreatic cancer. In order to prepare for late stage clinical trials, increased

Source: Cantargia signs agreement with Patheon Biologics B.V. for production of antibody CAN04

Booking.com
Booking.com

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.